HER2 is a biomarker of human breast cancer has become an important validated therapeutic target in breast cancer. Recently, a research published in Theranostics using OBOC to screen a library of novel HER2 targeting peptides. These targeting peptides were conjugated to DSPE-PEG-Maleimide (Nanosoft Polymers) to develop HER2 targeted liposomes for doxorubicin delivery to improve the cancer therapy and diagnosis. Geng L. et al. HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery. Theranostics. 2016: 6(8): 1261-1273.